dc.contributor.author | Murray, I | |
dc.contributor.author | Du, Y | |
dc.date.accessioned | 2021-01-18T14:21:03Z | |
dc.date.issued | 2021-02 | |
dc.identifier.citation | Clinical oncology (Royal College of Radiologists (Great Britain)), 2021, 33 (2), pp. 98 - 105 | |
dc.identifier.issn | 0936-6555 | |
dc.identifier.uri | https://repository.icr.ac.uk/handle/internal/4290 | |
dc.identifier.eissn | 1433-2981 | |
dc.identifier.doi | 10.1016/j.clon.2020.11.028 | |
dc.description.abstract | Treatments of bone metastases using radionuclides are now well established in oncology. It is also a field that continues to develop. This article reviews the evidence base that led to the approval of strontium-89 and samarium-153 ethylenediaminetetramethylene phophanate (EDTMP) for the palliation of pain from bone metastases, as well as the evidence for the use of radium-223 in metastatic castrate-resistant prostate cancer. Efforts to optimise treatments and improve response rates, either by safely increasing the radiation dose to bone metastases or by combining treatment with non-radiation-based therapies, are discussed. In addition, the development of both alpha- and beta-particle-emitting radiopharmaceuticals designed to target prostate-specific membrane antigen are reviewed. | |
dc.format | Print | |
dc.format.extent | 98 - 105 | |
dc.language | eng | |
dc.language.iso | eng | |
dc.title | Systemic Radiotherapy of Bone Metastases With Radionuclides. | |
dc.type | Journal Article | |
dcterms.dateAccepted | 2020-11-30 | |
rioxxterms.versionofrecord | 10.1016/j.clon.2020.11.028 | |
rioxxterms.licenseref.startdate | 2021-02 | |
rioxxterms.type | Journal Article/Review | |
dc.relation.isPartOf | Clinical oncology (Royal College of Radiologists (Great Britain)) | |
pubs.issue | 2 | |
pubs.notes | Not known | |
pubs.organisational-group | /ICR | |
pubs.organisational-group | /ICR | |
pubs.publication-status | Accepted | |
pubs.volume | 33 | |
pubs.embargo.terms | Not known | |
dc.contributor.icrauthor | Murray, | en |